Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
Anna Galanopoulos1, Ivan Goldberg21Senior Visiting Ophthalmologist, South Australian Institute of Ophthalmology and Dept of Ophthalmology and Visual Sciences, University of Adelaide, South Australia; 2Clinical Associate Professor, University of Sydney, Australia; Head, Glaucoma Unit, Sydney Eye Hosp...
Enregistré dans:
Auteurs principaux: | Anna Galanopoulos, Ivan Goldberg |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/eb440bd0135d4fe88ba06a90c277e32b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
par: Sharma S, et autres
Publié: (2015) -
Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
par: Whitson JT, et autres
Publié: (2013) -
Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
par: Baiza-Durán LM, et autres
Publié: (2012) -
Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma
par: Dimitris Papaconstantinou, et autres
Publié: (2009) -
Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
par: Wang N, et autres
Publié: (2020)